Automate theme → scenario → plan
In the app, we make it easy to go from investment themes to Scenario Lab to a full thesis plan — without the busywork.
Investment Confidence in LLY Amid Competitive Landscape
LLY|March 28, 2026
Merkapital proprietary research generated from the same Thesis Plan engine (news narrative → scenario overlay → risk framework → listed-options context). For information only — not a recommendation or personalized advice.
Executive Summary
- •Thesis: Recent investments and updates from major funds signal bullish sentiment for LLY, while the competitive landscape poses risks.
- •Reference spot: $878.24 · Scenario-implied fair value: — · Upside anchor: $1,209.34 (~+37.7% vs spot)
- •Risk framework: Volatility-adjusted stop at $831.03 (~5.4% below spot); risk/reward 7.01 : 1 vs modeled upside anchor.
- •Derivatives: Bull call spread candidates at ~6 months and ~12 months to expiration.
Overview metrics
Quantitative snapshot from the Merkapital dashboard (same fields as Stocks → Overview Metrics), frozen at Thesis Plan save time.
Merkapital proprietary research (public sample)
Key developments & media context
Catalyst / news flow (seed narrative)
The following item was flagged in Market Intelligence and used as the primary media input for this note. It frames the narrative that the Thesis Plan engine then maps into scenarios, risk/reward, and options structure — it is not a stand-alone fundamental view.
Headline-level classification and feed sentiment skew constructive (risk-on). We treat this item as the narrative seed for the bull / base / bear structure and scenario overlay that follow — not as a standalone forecast.
Primary headline
Korean Firms Accelerate Monthly Obesity Treatment Development
Feed tone label: Somewhat-Bullish.
LLY · LLY · LLY · LLY · LLY
large-scale production.
https://www.chosun.com/english/industry-en/2026/03/26/E7LQD2EQJZE5PISOEZT4L6POWM/
Merkapital proprietary research (public sample)
Revenue scenario
The following reflects consolidated revenue and segment mix assumptions recorded at the time this report was generated, benchmarked to the mapped segment disclosure and SEC-sourced consolidated revenue where applicable. Competitive positioning and filing references are provided for context only. These amounts represent hypothetical scenario inputs prepared in the research workflow and are not forecasts, targets, or projections of actual results.
Scenario basis: Forward analyst revenue estimate for the period ending December 31, 2027. Segment mix is benchmarked to the competitive map segment disclosure (FY 2025 (period end 2025-12-31)).
| Segment | Map % | Thesis % |
|---|---|---|
| Diabetes Care | 45.0% | 45.0% |
| Oncology | 30.0% | 30.0% |
| Immunology | 15.0% | 15.0% |
| Neuroscience | 10.0% | 10.0% |
leader
$65.18B
FY 2025 (period end 2025-12-31)
Diabetes Care · Oncology · Immunology · Neuroscience
Merkapital proprietary research (public sample)
Scenario Lab
Earnings and multiple assumptions from the Thesis Plan wizard (step 3), prior to the execution plan below.
- Last close
- $878.24
- Consensus EPS (next FY, baseline)
- —
- Scenario EPS
- —
- Forward P/E (baseline)
- —
- Scenario forward P/E
- —
- Street-implied (baseline)
- $1,209.34
- Scenario implied fair value
- $1,209.34
- Analyst target
- $1,209.34
- Scenario vs spot
- +37.7%
Frozen at Thesis Plan save; does not update with live quotes.
Merkapital proprietary research (public sample)
Valuation & Scenario Overlay
| Metric | Value |
|---|---|
| Last / model spot | $878.24 |
| Consensus analyst target (where available) | $1,209.34 |
| Scenario Lab implied price | — |
| Thesis upside anchor (options / R:R) | $1,209.34 |
| ATR-style volatility proxy (14d scale) | $31.47 |
| Annualized vol (model) | 35.6% |
| Risk per share (spot − stop) | $47.21 |
| Reward per share (anchor − spot) | $331.10 |
Merkapital proprietary research (public sample)
Risk Management & Invalidation
Volatility-adjusted stop: consider closing or reducing if price ≤ $831.03 (entry − 1.5× ATR proxy using model volatility). Scenario upside anchor: $1209.34. Educational workflow only — not advice.
Merkapital proprietary research (public sample)
Listed Options — Expression of View
Structures are algorithmically selected from available chains (bull call spread; ~6m and ~12m anchors). Quotes may be delayed; liquidity and execution assumptions not modeled here.
Bull call spread: defined risk, long gamma. Cost under 2% of underlying.
Merkapital proprietary research (public sample)
Investment Thesis Map
Investment Confidence in LLY Amid Competitive Landscape
Constructive angles
Increased institutional investment indicates strong confidence in LLY's growth.
LLY
Pensionfund Sabic and Janus Henderson have made new investments in LLY, suggesting institutional confidence.
Mechanism: Higher institutional ownership can drive stock prices up due to perceived stability and growth potential.
LLY's advancements in obesity treatment position it favorably against competitors.
LLY
Korean firms are accelerating their development of obesity treatments, indicating a growing market.
Mechanism: LLY's established presence and ongoing innovation in this area could capture significant market share.
Cautious / bearish angles
Lack of ownership by major funds raises concerns about LLY's market perception.
LLY
Vanguard's disaggregation shows zero shares owned in LLY, which may signal a lack of confidence.
Mechanism: Low ownership by influential funds can lead to reduced investor interest and stock price pressure.
Increased competition in the obesity treatment space could impact LLY's market position.
MRK, PFE
As competitors like Merck (MRK) and Pfizer (PFE) ramp up their efforts, LLY may face market share erosion.
Mechanism: Heightened competition can lead to pricing pressures and reduced margins for LLY.
Second-order effects
- Increased institutional investment could lead to higher stock volatility as new investors enter and exit positions.
- If LLY successfully captures market share in obesity treatments, it could spur further investments in related biotech sectors.
Risks & invalidation
- If competitive pressures lead to significant market share loss, LLY's growth narrative could be invalidated.
- Negative sentiment from major funds could continue to affect LLY's stock price and investor confidence.
Suggested news monitors
Eli Lilly investment news · LLY obesity treatment developments · Institutional ownership changes for LLY · Competitive analysis in biotech sector
This document is generated by Merkapital's research tooling for informational and educational purposes only. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security or derivative. Scenario outputs depend on user inputs and model assumptions; actual results may differ materially.
Options involve substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
Automate theme → scenario → plan
Build investment themes, stress-test them in Scenario Lab, and turn the winner into a thesis plan — faster than spreadsheets and copy-paste.
Create your 10x idea today